



22783 U.S.PTO

Box Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT
Attorney Docket No.: ABSALUS-08602

17302 U.S.PTO
10/770668

020204

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of Susan C. Wright, James W. Lerrick, David S. Wilson and Steffen R. Nock for **Cell-Killing Molecules and Methods of Use Thereof**.

CERTIFICATION UNDER 37 C.F.R. § 1.10

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the U.S. Postal Service on this date **February 2, 2004** in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number **EV 329 476 545** US addressed to: **Box Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.



Karen B. Webber

1. Type Of Application

This new application is for a(n)

Original (nonprovisional)

2. Benefit Of Prior U.S. Application(s) (35 U.S.C. §§ 119(e), 120, or 121)

The new application being transmitted claims the benefit of prior U.S. application(s) and enclosed are **ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED**.

3. Papers Enclosed That Are Required For Filing Date Under 37 C.F.R. § 1.53(b) (Regular) or 37 C.F.R. § 1.153 (Design) Application

139 Pages of Specification

4 Pages of Claims

1 Page of Abstract

8 Sheets of Formal Drawings

4. Additional Papers Enclosed

Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.

Certificate Re: Sequence Listing

5. Declaration by inventors

Enclosed (unexecuted)

6. Inventorship Statement

The inventorship for all the claims in this application is:

the same

7. Language

English

8. Assignment

An assignment (unexecuted) of the invention to **Palo Alto Institute of Molecular Medicine** is attached.

Form PTO-1595 will follow.

9. Fee Calculation (37 C.F.R. § 1.16)

Regular application

CLAIMS AS FILED

Number Filed	Number Extra	Rate	Basic Fee - \$770.00 (37 C.F.R. § 1.16(a))
Total Claims (37 C.F.R. § 1.16(c))	47 - 20 =	27 × \$18.00 =	\$486.00
Independent Claims (37 C.F.R. § 1.16(b))	7 - 3 =	4 × \$86.00 =	\$344.00
Multiple Dependent Claim(s), if any (37 C.F.R. § 1.16(d))		+ \$290.00 =	\$0.00

Filing Fee Calculation \$1600.00

10. Small Entity Statement(s)

Verified Statement(s) that this is a filing by a small entity under 37 C.F.R. §§ 1.9 and 1.27.

Filing Fee Calculation (50% of above) \$800.00

11. Fee Payment Being Made At This Time

Enclosed

basic filing fee

Total Fees Enclosed \$800.00

12. Method of Payment of Fees

Check in the amount of \$800.00

13. Authorization To Charge Additional Fees and Credit Overpayment

The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No.: 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

14. Power of Attorney by Assignee

Enclosed (unexecuted)

15. Return Receipt Postcard

Enclosed

Dated: February 2, 2004



Signed by: Christine A. Lekutis, Reg. No. 51,934
On behalf of: Maha A. Hamdan, Reg. No. 43,655

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415.904.6500

Incorporation By Reference Of Added Pages

Plus Added Pages For New Application Transmittal Where Benefit Of Prior U.S. Application(s)
Claimed

Number of pages added 1

The PTO did not receive the following
listed item(s) plus check \$800.00
but we received \$880.00

**ADDED PAGES FOR APPLICATION TRANSMITTAL
WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED**

16. Relate Back

A. **35 U.S.C. § 119(e)**

B. **35 U.S.C. §§ 120, 121 and 365(c)**

"This application claims priority to U.S. Provisional Application Serial Nos. 60/444,191, filed February 3, 2003 and 60/460,855, filed April 8, 2003, the contents of each of which are incorporated herein in their entirety."

17. Further Inventorship Statement Where Benefit Of Prior Application(s) Claimed

a. The inventors in this application are the same as in the prior applications.